ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fludarabine

Also written as “Fludarabine”, “Cyclophosphamide,Fludarabine” and “TC-D101 CAR-T”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Non-Hodgkin · Glioblastoma, led by 18 companies.

Drug pageFludarabine: every studyMany companies study it; this page follows only the 35 they lead. All 745 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 5, 202635 company-led studies, 21 open or runningNext primary completion: Jan 14, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotechits history only99 open or runningphase 2since Apr 5, 2026Mar 14, 2026Feb 18, 2027phase 1 · NCT07480941
Hoffmann-La Rocheits history only60 open or runningphase 4since Jan 4, 2011Oct 16, 2007none ahead
Allogene Therapeuticsits history only32 open or runningphase 2since Dec 8, 2022Dec 8, 2022Dec 2027phase 2 · NCT06500273
Hangzhou Huasai Biomedicineits history only22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
Shanghai First Song Biotechnologyits history only21 open or runningearly phase 1since Jul 30, 2024Jul 30, 2024none ahead
Adicet Therapeuticsits history only10 open or runningphase 1since Jan 26, 2021Jan 26, 2021none ahead
Biotech Equity Partners Ptyits history only10 open or runningphase 1since Feb 20, 2008Feb 20, 2008none ahead
Bristol-Myers Squibbits history only11 open or runningphase 1since Feb 7, 2025Feb 7, 2025Mar 15, 2029phase 1 · NCT07115745
Caribou Biosciencesits history only11 open or runningphase 1since Nov 16, 2020Nov 16, 2020none ahead
CARsgen Therapeuticsits history only10 open or runningphase 1since Aug 9, 2016Aug 9, 2016none ahead
Precision BioSciences10 open or runningphase 2since Jul 19, 2019Jul 19, 2019none ahead

Also a collaborator on its studies: Natera.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2019First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT04030195 · 18 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Precision BioSciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04030195Lymphoma, Non-Hodgkin · United States2CompletedJun 24, 202118

How it is read

Names in the registry

  • “Fludarabine”, 40 entries
  • “Cyclophosphamide,Fludarabine”, 4 entries
  • “TC-D101 CAR-T”, 1 entry
  • “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells”, 1 entry
  • “fludarabine, rituximab, pixantrone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.